Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs iShares Core S&P 500 ETF (IVV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs iShares Core S&P 500 ETF — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $281.5 (market cap $39.89B), while iShares Core S&P 500 ETF trades at $755.6. The key difference: iShares Core S&P 500 ETF is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | IVV | |
|---|---|---|
Market Cap | $39.89B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $491.22 | $763.10 |
52-Week Low | $278.09 | $624.65 |
Enterprise Value | $38.15B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
IVV, tracking the S&P 500, trades at $758.39, up 0.43% on the day, with a bullish technical signal from moving averages and support near $751. The index is approaching record highs, driven by AI-led tech strength and robust earnings forecasts, though RSI levels indicate potential overbought conditions. A dividend of $2.00 is scheduled for June 2026.
The outlook remains positive given strong AI-driven earnings growth and institutional optimism, with targets like 8,250 cited by Yardeni Research (July 7, 2026). Risks include Fed policy shifts, geopolitical tensions, and high valuations; investors should focus on earnings momentum amid sector rotations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About iShares Core S&P 500 ETF
IVV tracks the performance of the S&P 500 Index, offering low-cost exposure to 500 of the largest US companies. It is a cornerstone for long-term investors seeking broad growth in the US stock market.
Read more on IVV →
